Anti-CTLA4 antibodies and methods of making and using the same

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 11692036
APP PUB NO 20210206855A1
SERIAL NO

16966844

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Provided herein are cross-reactive antibodies (or antigen binding fragments thereof) that bind to human CTLA4, activatable antibodies that bind to human CTLA4, nucleic acid molecules encoding the same, pharmaceutical compositions thereof, and methods of their therapeutic use (e.g., for treatment of cancer).

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • ADAGENE INC.

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Du, Fangyong Jiangsu, CN 19 31
Liu, Guizhong Jiangsu, CN 12 18
Luo, Peter Peizhi San Mateo, US 26 220
Pan, Zhongzong Jiangsu, CN 5 4

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 Jan 4, 2027
7.5 Year Payment $3600.00 $1800.00 $900.00 Jan 4, 2031
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jan 4, 2035
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00